Vincerx Pharma, Inc. (VINC)
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
Sector: Biotechnology
Industry: Biotechnology
Vincerx Pharma, Inc.
- 0.0%
- 966
- 1.23
Float 5.23M · Signal8 estimate from ownership filings · Apr 9, 2024
The cost to borrow VINC shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 6.0%
- No fails on record for 16–31 Oct 2026.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 966 sh |
| Oct 15, 2026 | 966 sh |
| Sep 30, 2026 | 966 sh |
| Sep 15, 2026 | 966 sh |
| Aug 31, 2026 | 966 sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 11, 2026 | 6.0% |
| Nov 4, 2026 | 0.9% |
| Nov 2, 2026 | 100.0% |
| Oct 9, 2026 | 0.2% |
| Sep 17, 2026 | 100.0% |
130 calendar days requested; 10 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for VINC: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 966 VINC shares were sold short (0.02% of a 5.23M-share float, 1.23 days to cover).